Segments (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Expenses

The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under U.S. GAAP to the Company’s total net loss in the statements of operations (in thousands).

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Operating expenses:
Bexotegrast - clinical trial and third party contracting costs	4,526		26,713		39,474		70,290
Employee-related expenses - research and development (excluding stock-based compensation)	5,180		8,778		26,010		26,297
General and administrative costs (excluding stock-based compensation)	6,261		8,963		25,497		26,089
Other segment items	12,302		17,560		41,815		52,369
Segment loss	28,269		62,014		132,796		175,045
Reconciliation of segment loss
Interest and other (income) expense, net	(2,783)		(5,128)		(9,452)		(16,663)
Interest expense	815		877		2,423		2,190
Net loss	$	26,301	$	57,763	$	125,767	$	160,572